PMID- 29681195
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190410
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 18
IP  - 6
DP  - 2018 Jun
TI  - Biologics for treating axial spondyloarthritis.
PG  - 641-652
LID - 10.1080/14712598.2018.1468884 [doi]
AB  - INTRODUCTION: Spondyloarthritis (SpA) encompasses a heterogeneous group of 
      diseases sharing genetic, immunological, clinical and imaging features. Axial 
      spondyloarthritis (axSpA) refers to a subgroup characterised predominately by 
      inflammation of the axial skeleton with subsequent symptoms of chronic (often 
      inflammatory) back pain and sacroiliitis. There is a strong association with the 
      major histocompatibility complex (MHC) class I allele human leukocyte antigen 
      (HLA) B27. In the last decade, there has been significant progress in earlier 
      detection of the disease and the molecular mechanisms involved in its 
      pathogenesis. The subsequent introduction of anti-tumour necrosis factor (TNF) 
      has revolutionised the treatment of patients with axSpA. AREAS COVERED: In this 
      article, we review the current biologic therapies for axSpA, the emergence of 
      biosimilars, predictors of response, primary and secondary failure and new 
      biologics on the horizon. EXPERT OPINION: There have been significant advances in 
      the treatment of axSpA. Beyond the clear efficacy of anti-TNF inhibition, IL-17 
      offers an alternative therapeutic target and there is promise from inhibition of 
      the IL-17/IL-23 pathway and small molecules, such as Janus kinase (JAK) 
      inhibitors. Biosimilars have offered greater affordability and choice within this 
      increasingly growing field of therapeutics.
FAU - Jones, Alexis
AU  - Jones A
AD  - a Rheumatology Department , University College London Hospitals, NHS Foundation 
      Trust , London , United Kingdom of Great Britain and Northern Ireland.
FAU - Ciurtin, Coziana
AU  - Ciurtin C
AD  - b University College London Hospitals, NHS Foundation Trust , London , United 
      Kingdom of Great Britain and Northern Ireland.
FAU - Ismajli, Mediola
AU  - Ismajli M
AD  - c Rheumatology Department , Chelsea and Westminster Hospital, NHS Foundation 
      Trust , London , United Kingdom of Great Britain and Northern Ireland.
FAU - Leandro, Maria
AU  - Leandro M
AD  - b University College London Hospitals, NHS Foundation Trust , London , United 
      Kingdom of Great Britain and Northern Ireland.
FAU - Sengupta, Raj
AU  - Sengupta R
AD  - d Royal National Hospital For Rheumatic Diseases , Bath , United Kingdom of Great 
      Britain and Northern Ireland.
FAU - Machado, Pedro M
AU  - Machado PM
AD  - e Centre for Rheumatology & MRC Centre for Neuromuscular Diseases , University 
      College London , London , United Kingdom of Great Britain and Northern Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180507
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0 (IL17A protein, human)
RN  - 0 (Interleukin-17)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Back Pain/drug therapy/etiology
MH  - Biosimilar Pharmaceuticals/*therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Interleukin-17/antagonists & inhibitors
MH  - Spondylarthritis/complications/*drug therapy/epidemiology
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
OTO - NOTNLM
OT  - Spondyloarthritis
OT  - ankylosing spondylitis
OT  - anti-IL17
OT  - anti-TNF
OT  - biologics
OT  - biosimilars
EDAT- 2018/04/24 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/04/24 06:00
PHST- 2018/04/24 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/04/24 06:00 [entrez]
AID - 10.1080/14712598.2018.1468884 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2018 Jun;18(6):641-652. doi: 
      10.1080/14712598.2018.1468884. Epub 2018 May 7.